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Abstract
Background: Around one in ten adults take antidepressants for depression in England, and their long-term use is
increasing. Some need them to prevent relapse, but 30–50% could possibly stop them without relapsing and avoid
adverse effects and complications of long-term use. However, stopping is not always easy due to withdrawal
symptoms and a fear of relapse of depression. When general practitioners review patients on long-term
antidepressants and recommend to those who are suitable to stop the medication, only 6–8% are able to stop. The
Reviewing long-term antidepressant use by careful monitoring in everyday practice (REDUCE) research programme
aims to identify safe and cost-effective ways of helping patients taking long-term antidepressants taper off
treatment when appropriate.
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Methods: Design: REDUCE is a two-arm, 1:1 parallel group randomised controlled trial, with randomisation
clustered by participating family practices. Setting: England and north Wales. Population: patients taking
antidepressants for longer than 1 year for a first episode of depression or longer than 2 years for repeated episodes
of depression who are no longer depressed and want to try to taper off their antidepressant use. Intervention:
provision of ‘ADvisor’ internet programmes to general practitioners or nurse practitioners and to patients designed
to support antidepressant withdrawal, plus three patient telephone calls from a psychological wellbeing
practitioner. The control arm receives usual care. Blinding of patients, practitioners and researchers is not possible in
an open pragmatic trial, but statistical and health economic data analysts will remain blind to allocation. Outcome
measures: the primary outcome is self-reported nine-item Patient Health Questionnaire at 6 months for depressive
symptoms. Secondary outcomes: depressive symptoms at other follow-up time points, anxiety, discontinuation of
antidepressants, social functioning, wellbeing, enablement, quality of life, satisfaction, and use of health services for
costs. Sample size: 402 patients (201 intervention and 201 controls) from 134 general practices recruited over 15–18
months, and followed-up at 3, 6, 9 and 12 months. A qualitative process evaluation will be conducted through
interviews with 15–20 patients and 15–20 practitioners in each arm to explore why the interventions were effective
or not, depending on the results.
Discussion: Helping patients reduce and stop antidepressants is often challenging for practitioners and time-
consuming for very busy primary care practices. If REDUCE provides evidence showing that access to internet and
telephone support enables more patients to stop treatment without increasing depression we will try to implement
the intervention throughout the National Health Service, publishing practical guidance for professionals and advice
for patients to follow, publicised through patient support groups.
Trial registration: ISRCTN:12417565. Registered on 7 October 2019.
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Introduction
Background and rationale {6a}
Antidepressant prescriptions have risen steadily year
on year since 1990 because general practitioners
(GPs) have been prescribing longer and longer
courses [1, 2], and the average length of treatment is
now more than 2 years. Some people need long-term
antidepressants to prevent relapse, but surveys suggest
30–50% have no evidence-based indication for long-
term use [3]. However, stopping is not easy due to
withdrawal symptoms including anxiety and mood
changes, which feel similar to the reason why treat-
ment was started in the first place [4]. Patients on
long-term treatment are often given repeat prescrip-
tions and are reviewed only infrequently [5, 6].
Taking antidepressants over the long term exposes
patients to the risks of side effects. Common side effects
of antidepressants include changes in weight, changes in
sleep and sexual dysfunction [7]. Less commonly, some
patients develop bleeding from the stomach or intestine,
and the use of antidepressants in people aged over 65
years is associated with an increase in the risks of falls,
seizures and strokes [8]. Around one in two patients on
antidepressants feel emotional blunting or numbness [9];
thus, the drugs should not be continued over the long
term unless there is a good reason for taking them.
Antidepressants constitute a substantial proportion of
the National Health Service (NHS) drug budget (2.5% in
2010 [10]), and the costs of unnecessary treatment
include appointments for medical or nursing reviews.
The cost of GP care for depression was estimated to be
£200 m per year in 2006 [11], in addition to the cost of
the antidepressant prescriptions of around £300m per
year, so substantial savings could be made if significant
numbers of long-term users were to discontinue.
Many patients are dissatisfied with this situation and
would like help to stop long-term treatment. However,
GPs often lack experience in reducing antidepressant
medication flexibly, and GP advice to taper and stop
treatment is not often successful. Prompting GPs to re-
view patients eligible for stopping treatment was tested
in a trial in the Netherlands and found to be ineffective,
with only 6% of patients discontinuing in the interven-
tion group and 8% in the control group [12, 13].
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Similarly, an uncontrolled trial of pharmacist-prompted
GP review of long-term users in Scotland resulted in
only 7% stopping [14]. Therefore, it appears that with-
out a specific intervention addressing issues with pa-
tient and practitioner behaviours, many patients will
continue antidepressants unnecessarily. Practitioners
need guidance to provide support for tapering and
stopping treatment, and patients need further support
and advice on coping with withdrawal symptoms.
The aim of the REDUCE programme is to identify
feasible, safe, effective and cost-effective ways of helping
patients taking long-term antidepressants taper and stop
treatment when appropriate.
Objectives {7}
1) To determine the effectiveness of the intervention
through a randomised controlled trial
2) To estimate cost-effectiveness from a health and
personal social service perspective, with a sensitivity
analysis from a societal perspective.
Trial design {8}
REDUCE is a two-arm, 1:1 parallel group randomised
controlled trial, with randomisation clustered by partici-
pating family practices to avoid contamination between
intervention and control arms.
Methods: participants, interventions and
outcomes
This is protocol version 1.4, dated 28 November 2019.
Study setting {9}
The study setting is primary care (group general family
practices) in England and north Wales recruited from
the Universities of Southampton, Liverpool and Hull. A
full list of study sites can be obtained by email from
reduce@soton.ac.uk.
Eligibility criteria {10}
Our aim is to include patients who are taking long-term
antidepressant treatment that is not indicated according
to the National Institute for Health and Care Excellence
depression guideline [15]. We will therefore include all
consenting patients on treatment for more than 1 year
for a first episode, and patients treated for more than 2
years for a recurrent episode, who are no longer de-
pressed or judged to be at significant risk of relapse.
The significant risk factors for relapse are: current
significant depressive symptoms on the nine-item Patient
Health Questionnaire (PHQ-9; see below) despite anti-
depressant treatment, current significant anxiety symp-
toms on the seven-item Generalised Anxiety Disorder
(GAD-7) rating scale (see below), current suicidal ideas
(see below) and current psychiatric outpatient or inpatient
treatment for depression.
In addition to the above criteria increasing the risk of
relapse, the following are also exclusion criteria: bipolar
disorder, comorbid psychosis, substance use, dementia
as a primary diagnosis, spoken or written English
language inadequate to take part in interviews or
complete questionnaires, and another indication for
taking antidepressants (e.g. neuropathic pain).
Who will take informed consent? {26a}
Patients on long-term antidepressants are identified
through searches of computerised practice medical rec-
ord databases, mailed a patient information sheet (PIS)
about the study by the practice and asked to contact the
study team if they wish to take part, or to decline, using
a reply slip and a freepost envelope after they have had
time to consider. If they do not respond the research
team will have no knowledge of them, maintaining
patient confidentiality, and this will not prejudice their
future treatment. If patients do respond positively to ei-
ther approach, a member of the research team will then
contact them, screen them by telephone for any exclu-
sion criteria, and arrange to see them face to face for a
baseline visit if they are eligible. At baseline, the re-
searcher will go over the PIS again and seek formal writ-
ten consent.
All patients are told we are recruiting people who
have been taking antidepressants for more than 1
year for a first episode, or more than 2 years for a
recurrent episode, with a view to working out how to
help them reduce their medication, if appropriate,
with the advice of their practice GP or nurse. The
PIS outlines the two different approaches in the
intervention and control arms, but not in detail, and
potential participants do not know at this point to
which arm their general practice has been
randomised. This is to avoid differential rates of
consent to the two arms based on patients’ opinions
of the intervention or procedures involved in each.
Having consented to take part in writing on this initial
basis, and having undergone baseline assessment, patients
will then be given further information about the details of
the procedures in the arm to which their practice has
been randomised.
Patients who do not wish to consent to take part at
that point for reasons that may be temporary (i.e. they
do wish to try to reduce and stop taking their
antidepressant, but not at that time due to current life
stresses, recent life events, or the timing of upcoming
events and so forth) have the option of consenting to be
re-contacted after 3 months to be asked again if they
wish to participate at that later point.
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Additional consent provisions for collection and use of
participant data and biological specimens {26b}
This trial does not involve collecting biological
specimens for storage.
Interventions
Explanation for the choice of comparators {6b}
The intervention consists of GP or nurse practitioner
(NP) and patient access to ‘ADvisor’ internet programmes
designed to support antidepressant withdrawal, plus three
patient telephone calls from a psychological wellbeing
practitioner. Control patients receive usual care without
internet or telephone support, but patients are prompted
to seek a review of their long-term antidepressant treat-
ment at the start of their involvement in the trial and may
also decide to try to taper off their antidepressant use in
discussion with their GP or NP.
Intervention description {11a}
The practitioner intervention (called ‘ADvisor for Health
Professionals’ as it gives advice about antidepressants)
includes internet modules on: why reduce; broaching the
subject; when to start tapering; reduction schedules for
individual antidepressants; dealing with withdrawal
symptoms; dealing with relapse; a summary of the ADvisor
intervention for patients; and printable pages on
antidepressant reduction regimes and sections of ADvisor
for patients that are recommended for the patients to
consult. The intervention broadly targets increasing the
self-efficacy of GPs and NPs to safely discontinue patients
from antidepressants where appropriate. It was developed
using evidence and theory in combination with in-depth
qualitative interviews/focus groups with GPs/NPs. A paper
describing the development of the health professional inter-
vention is being prepared for submisison for publication in
another journal, which is what we mean by 'elsewhere'.
The patient intervention (called ADvisor) has also
been developed drawing on theory, evidence and in-
depth systematic qualitative research with patients, and
has been more fully described elsewhere [16]. As in the
health professional intervention, our aim is to increase
patients’ self-efficacy for stopping antidepressants in a
way that is safe and suited to their preferences. We fo-
cused on increasing patients’ reflective motivation for
stopping, and supporting their psychological and phys-
ical capability to do so through internet modules that in-
clude: reducing and stopping (introduction to website);
how to reduce antidepressants; thinking about antide-
pressants (their effects and why lifelong treatment may
not be necessary); dealing with withdrawal symptoms; I
am worried about stopping; keeping well; thinking about
what you value in life; and moving forward.
In the intervention arm practices, the GPs/NPs are
given access and an introduction to the online ADvisor
for Health Professionals and induction to the study,
which is either practice-based or online. Through read-
ing ADvisor for Health Professionals, they receive educa-
tion on best practice in the supervision of antidepressant
tapering and cessation, focussing on the differences be-
tween withdrawal symptoms and relapse, and the man-
agement of withdrawal symptoms.
As patients are recruited to the intervention arm they
are asked to make an appointment with their GP/NP to
discuss coming off their antidepressant and agreeing an
initial dosage tapering schedule. The number and timing
of subsequent GP/NP consultations during tapering and
following drug cessation is left to the participating GPs/
NPs to agree with the patients on an individual basis.
In addition to the ADvisor internet modules and GP/
NP consultations, the following telephone support is
provided to patients in the intervention arm by a trained
psychological wellbeing practitioner:
 Call 1 (0–2 weeks), for 30 min: to check the patient’s
understanding of the ADvisor intervention and
encourage confidence in going through the tapering
and cessation process
 Call 2 (4–6 weeks), for 15 min: to ask the patient
how tapering is going and whether they are
following the schedule and, where necessary, to
advise the patient to discuss any issues with tapering
with their GP
 Call 3 (timing agreed with patient), for 15 min: to
ask the patient about any residual withdrawal
symptoms and go over techniques to help with
relapse prevention.
A sample of 10–20 telephone calls per practitioner will
be audiorecorded in the first 3 months, and again
halfway through the trial, to check for fidelity against the
telephone support guide.
In the control arm, participating practices are
informed that the recruited patients are potentially
eligible for tapering off antidepressants. Their electronic
medical records are flagged and, as they are recruited,
patients are asked to make an appointment as part of
usual care to see their GPs/NPs for a review of the need
for their antidepressant medication, but the practitioners
are not given the ADvisor for Health Professionals
information on best practice in tapering, unlike
practitioners in the intervention arm.
Alerting the control arm practices to the potential
eligibility of patients for tapering off antidepressants will
result in some patients tapering and ceasing treatment. This
will be permitted within the trial. Our power calculation for
the secondary outcome of antidepressant discontinuation in
the main trial assumes a 7% discontinuation rate in the
control practices, which is the rate found in previous studies
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of simply prompting GPs to review patients potentially
eligible for discontinuation [13, 14].
Criteria for discontinuing or modifying allocated
interventions {11b}
There are no specific criteria for discontinuing or
modifying allocated interventions at the time of writing.
The Independent Data Monitoring Committee (IDMC)
will monitor the progress of the trial, decide whether
any interim analyses are necessary, decide whether there
are circumstances under which the trial should be
stopped, and make their recommendations to the
Programme Steering Committee (PSC).
Strategies to improve adherence to interventions {11c}
The three psychological wellbeing practitioner telephone
calls are aimed at encouraging patients in the
intervention arm to use the internet support. Patients’
use of the internet programme is automatically recorded
to allow estimation of adherence to the intervention.
Relevant concomitant care permitted or prohibited during
the trial {11d}
Practitioners are free to refer patients to other sources of
help in both arms (e.g. referral for psychological therapy).
Provisions for post-trial care {30}
Participating patients remain under the usual care of the
treating practitioner.
Outcomes {12}
Outcome measures are collected at baseline and at 3, 6,
9 and 12 months (see Table 1 for exact timings). The
primary outcome is the PHQ-9 score for depressive
symptoms at 6 months. We will also consider this out-
come using a repeated measures approach over the full
12 months of follow-up with a generalised linear mixed
model allowing for responses clustered within partici-
pants over time and participants clustered within prac-
tices. Secondary outcomes are: anxiety; discontinuation
of antidepressants (at 6 months, for at least 2 months);
mental wellbeing; antidepressant withdrawal symptoms;
antidepressant side effects; patient satisfaction; patient
enablement; quality of life; and use of health services to
calculate costs.
The PHQ-9 [17] is a self-complete questionnaire tak-
ing approximately 3 min to complete. It measures nine
core symptoms of depression based on the Diagnostic
and Statistical Manual fourth edition criteria and has
high sensitivity and specificity in UK primary care [18].
The GAD-7 is a brief instrument for measuring anx-
iety, which has also been validated in primary care [19].
Although originally developed to detect GAD, it also has
good sensitivity and specificity for panic, social anxiety,
and post-traumatic stress disorders [20].
Discontinuation of antidepressants is deemed to have
occurred once the patient has stopped taking them for 2
months. Determining discontinuation after 6 months
allows tapering and cessation to take up to 4 months. In
Table 1. Data collection summary
Measure Baseline
(face to face)
3 months
(postal or online)
6 months
(face to face)
9 months
(postal or online)
12 months
(face to face)
Sociodemographics and past history of
depression questionnaire
√
Depression (PHQ-9) √ √ √ √ √
Anxiety (GAD-7) √ √ √ √ √
Suicidal ideas √ √ √ √ √
Discontinuation of antidepressants
(for at least 2 months, by 6 months)
√
Quality of life (EQ-5D-5L, SF-12) √ √ √ √ √
Wellbeing (WEMWBS) √ √ √
Withdrawal symptoms (DESS) √ √ √
Antidepressant side effects (ASEC, CSFQ-C) (if taken) √ √ √
Satisfaction (MISS-29) √ √
Enablement (PEI) √ √
Questionnaires on use of services, use of
antidepressants and sickness absence
√ √ √
Beliefs about antidepressants questionnaire √ √ √
Collective efficacy questionnaire √
ASEC antidepressant side-effects check-list, CSFQ-C Changes in Sexual Functioning Questionnaire, DESS Discontinuation Emergent Signs and Symptoms, EQ-5D-5L
EuroQol five dimensions with five levels, GAD-7 seven-item Generalised Anxiety Disorder, MISS-29 29-item Medical Informant Satisfaction Scale, PEI Patient
Enablement Instrument, PHQ-9 nine-item Patient Health Questionnaire, SF-12 12-item Short Form, WEMWBS Warwick–Edinburgh Mental Wellbeing Scale
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our experience, after 2 months, withdrawal symptoms will
have mostly gone, and mood problems will have re-
emerged if they are going to. We believe patients who de-
cide to resume treatment are unlikely to wait even 1
month.
We are using the Warwick–Edinburgh Mental
Wellbeing Scale (WEMWBS) [21] as an additional
secondary outcome measure since this measures both
subjective experiences of happiness and life satisfaction
(the ‘hedonic perspective’), and positive psychological
functioning, good relationships with others and self-
realisation (the ‘eudaimonic perspective’). The latter in-
cludes capacity for self-development, positive relations
with others, autonomy, self-acceptance and competence.
Coming off long-term antidepressants might improve
these aspects of wellbeing since side effects can include
emotional blunting ,which should be reduced, and a
greater sense of autonomy and self-acceptance might re-
sult from not having to rely on medication. WEMWBS
has been shown to be responsive to change with a range
of mental health interventions in specialist and commu-
nity populations [22].
Antidepressant withdrawal symptoms are measured
using the Discontinuation Emergent Signs and Symptoms
scale, a brief self-report measure on which participants
can indicate the presence of, and changes in, 43 possible
antidepressant withdrawal symptoms [23]. Withdrawal
symptoms are measured (for all patients, whether or not
they withdraw from antidepressants) at 3 and 6months,
asking patients to rate their presence looking back over
the period since recruitment.
Antidepressant side effects are measured at baseline and
at 6 and 12months (for all patients, whether or not they
withdraw from antidepressants) using the antidepressant
side-effects check-list developed by Aitchison as part of
the GENDEP research project (http://gendep.iop.kcl.ac.
uk/results.php). It asks participants to rate the presence of
21 possible side effects and also includes open questions
for other symptoms not listed, and demonstrates good
agreement between self-report and psychiatrists’ ratings
[24]. At baseline and at 6 and 12months we also use the
Changes in Sexual Functioning Questionnaire, a 14-item
self-rating instrument including five domains of sexual
functioning, which has been shown to be reliable and valid
in both clinical and research settings [25, 26].
Patient satisfaction is assessed using the 29-item Med-
ical Interview Satisfaction Scale which was developed in
the USA to assess patient satisfaction with individual
doctor–patient consultations and has been shown to be
valid and reliable in UK primary care [27]. We have
adapted it to rate patient satisfaction at the 6-month
follow-up, asking patients to look back over their consul-
tations with the GPs/NPs for advising on tapering and
cessation of antidepressants.
We use the Patient Enablement Instrument that is
designed to capture patients’ ability to understand the
nature of their problems and cope with their illness [28].
This was developed in primary care to be completed by
the patient after a consultation. We have adapted it to
rate patient enablement at the 6-month follow-up, look-
ing back over the whole period of the intervention, as
was done successfully in the ATEAM trial [29] when the
adapted measure proved sensitive to change.
We are measuring quality of life using the EuroQol
five dimensions with five levels (EQ-5D-5L) measure
[30]. The EQ-5D-5L is the measure favoured by the Na-
tional Institute for Health and Care Excellence in deter-
mining cost effectiveness when developing its clinical
guidelines. The EQ-5D-5L includes five dimensions:
mobility, self-care, usual activities, pain/discomfort, and
anxiety/depression, each scored on five levels (no prob-
lems, slight problems, some problems, severe problems
and extreme problems). It is an improvement on the ori-
ginal three-level EQ-5D-3L which was developed to re-
duce ceiling effects experienced with the EQ-5D-3L. We
will apply the EQ-5D-5L scoring algorithm and value set
for England to translate EQ-5D-5L data scores into util-
ity scores [31].
We also assess quality of life using the Medical
Outcomes Study-derived measure of functional health
status, the 12-item Short Form [32], from which utility
scores can be derived using the six-item Short Form
[33]. One reason for using both measures is that the six-
item Short Form may be more sensitive to changes in
quality of life related to mild depression than the EQ-
5D-5L [34]. We also do not know which measure will be
more sensitive to changes in quality of life resulting from
relief from antidepressant side effects on the one hand,
or withdrawal symptoms on the other, resulting from
antidepressant discontinuation. We therefore use the 12-
item Short Form in addition to the EQ-5D-5L in the
trial and explore the implication of quality of life gained
or lost in our study population in a sensitivity analysis.
The health economics analysis is being undertaken
from an NHS and personal social services perspective,
with a sensitivity analysis from a societal perspective
including time lost from work. Bespoke questionnaires
are used to collect data on health and social service
resource use, personal out of pocket spending, and time
off work. In addition, a review of patients’ computerised
GP records is conducted by practice staff at the end of
the patient’s involvement in the study to extract any
additional health service usage including medication,
primary care consultations, outpatient appointments,
accident and emergency department attendances, and
hospital admissions. All items will be costed using
appropriate data (e.g. British National Formulary,
Personal Social Service Research Unit and NHS
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reference costs), with informal care costed at minimum
wage level. The resource-use questionnaire is adminis-
tered face to face with patients at baseline and at 6 and
12months, asking them to look back over the previous
6 months at each point. The case note review is done by
general practice staff at the end of the 12 months of
follow-up.
Mediator and moderator measures
In addition to the outcomes listed above, a bespoke
questionnaire asking for patients’ beliefs about
antidepressants, and their cessation, developed by a
Southampton PhD student (RD-H), is administered at
the face-to-face assessments at baseline and at 3 and 12
months. This will enable a mediator analysis of possible
effects of changes in patients’ beliefs on changes in anti-
depressant use.
At the 3-month assessment point, we also administer
the collective efficacy questionnaire [35] which is a
measure of the strength of support for discontinuing an-
tidepressants that a participant perceives among their
important friends and family, and a possible moderator
of the success of the intervention.
Participant timeline {13}
The participant timeline is shown in Fig. 1.
Sample size {14}
To have 90% power, with a one-sided alpha of 2.5%, to
establish non-inferiority in terms of depressive symp-
toms within two points (estimated to be the minimal
clinically important difference) on the PHQ-9 at 6
months (standard deviation 5.4), we need 155 patients
followed up in each arm. Assuming a variable cluster
size of between 1 and 7 per practice (mean 3) and an
intra-cluster correlation coefficient of 0.012 (from the
Health Technology Assessment THREAD trial of treat-
ing mild-to-moderate depression in primary care [36]),
gives a 1.033 cluster design effect (based on a coefficient
of variation of 1.5/3 = 0.5, using the formula of Eldridge
[37]). Anticipating 20% do not comply with the interven-
tion and/or are lost to follow-up, we need to randomise
(155 × 2 × 1.036) / 0.8 = 402 patients (201 per arm) from
134 practices (67 per arm).
Recruitment {15}
Potential patient participants are approached in two
ways: 1) through practice records database searches; and
2) opportunistically in GP or NP consultations.
All eligible patients identified by searches are actively
approached in both intervention and control arms to
avoid the risk of selection bias inherent in relying only
on opportunistic recruitment by practitioners.
Practice computerised medical record databases are
searched using ‘Read’ diagnostic and symptom codes for
depressive diagnoses and symptoms, together with British
National Formulary chapter codes for antidepressants
taken over the previous 2 years. Standardised searches
were developed for the two main practice computer
systems SystmOne and EMIS, which can be given to
participating practices. Participating GPs check the lists of
potential participants against the inclusion and exclusion
criteria to ensure all are suitable to be invited to take part.
Mail-out packs to patients include an invitation letter
from the GP, the participant information leaflet (PIL)
and a reply slip for the patients to complete indicating
whether they are interested in taking part. We use the
Docmail digital mail-out facility where possible. Inter-
ested patients are asked to contact the REDUCE team
directly using the reply slips (in freepost envelopes) or
by email. If patients do not contact the research team
then the team has no knowledge of their names or ad-
dresses, thus maintaining patient confidentiality.
Eligible patients may also be invited to consider taking
part within a GP or NP consultation for depression.
Patients are provided by the practitioner with a pack
including the GP invitation letter, PIL and reply slip to
be returned directly to the research team using a
freepost envelope if the patient is interested in
discussing possible involvement in the trial. Again, there
Fig. 1. The participant timeline for the study. GP general practitioner, NP nurse practitioner, PP psychological practitioner
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is no contact between the research team and potential
patients unless the patients initiate it.
Those patients who return reply slips to the research
team indicating a willingness to discuss possible
participation are contacted by a member of the research
team by telephone and screened for the exclusion criteria.
This involves asking a standard set of yes/no questions
and administration of the PHQ-9 for depressive symptoms
and the GAD-7 for anxiety symptoms (see below). Pa-
tients are reminded of the information provided to them
in the PIL sent with the GP invitation letter, and if they
have no exclusion criteria they are asked for a convenient
time to meet with a member of the research team.
We ask the participating general practice if they would
like to send a reminder invitation to participate letter to
participants who do not respond to the first invitation to
participate. We think that some participants may not be
ready to taper their antidepressants when they receive
the first invitation for reasons that may be transient, for
example too close to Christmas. As people’s situations
and personal circumstances fluctuate, a follow-up letter
may be received at a time that the participant considers
more appropriate for tapering.
Assignment of interventions: allocation
Sequence generation {16a}
Randomisation of practices will be by computerised
sequence generation, and minimisation with a random
element using three factors to avoid imbalance between
the two arms: practice size (large/small), location (urban/
rural) and social deprivation (dichotomised around the
median Index of Multiple Deprivation score). The
allocation ratio is 1:1 but there is a random element to the
minimisation algorithm and so we might not expect
perfect balance to the randomisation.
Concealment mechanism {16b}
The allocation sequence is generated by the Southampton
Clinical Trials Unit separate to the research teams
recruiting the practices.
Implementation {16c}
Notification of allocation is online by the Clinical Trials
Unit. The research teams enrol the participant practices,
and the Clinical Trials Unit assigns participant practices
to intervention or control arms.
Assignment of interventions: blinding
Who will be blinded {17a}
Blinding of both patients and practitioners in the
intervention arm during patient recruitment and face-to-
face assessment is impossible given the cluster random-
isation of practices and the nature of the intervention.
Self-report outcome measures are therefore being used
to prevent observer rating bias by research team mem-
bers aware of the patient’s assigned trial arm. The statis-
ticians and health economists analysing the data are kept
blind to allocation.
Telephone follow-up where necessary will be carried
out by a research assistant in a different university to the
recruiting university, blind to practice allocation, who
will advise the patients on first contact not to reveal
which arm of the trial they are in. Any inadvertent
unblinding will be recorded and reported. The trial re-
search assistants will also obtain information from med-
ical records, but at the end of the study in order not to
unblind them to practice allocation during patient
follow-up.
Procedure for unblinding if needed {17b}
The statisticians and health economists analysing the
data will be unblinded to allocation only after all the
data have been collected, entered into the database, and
cleaned.
Data collection and management
Plans for assessment and collection of outcomes {18a}
Patients are initially screened by telephone and excluded
if they have any of the exclusion criteria. These include
significant depressive symptoms despite antidepressant
treatment defined as a score of 12 or more on the PHQ-
9 completed over the telephone. Patients are also ex-
cluded if they have significant anxiety at baseline, i.e. a
score of 10 or more on the GAD-7, also completed over
the telephone. If patients score above 0 (i.e. 1, 2 or 3) on
the ninth question of the PHQ-9 about suicide/self-harm
they are also excluded from participating, and this infor-
mation is relayed to their GP immediately for them to
discuss this, preferably with their permission. The infor-
mation may be relayed without their permission if neces-
sary, after discussion between the researcher, the
principal investigator and the patient.
The other exclusion criteria addressed through telephone
screening of patients include: current psychiatric outpatient
or inpatient treatment for depression (yes/no); comorbid
psychosis, substance use or dementia as a primary
diagnosis (yes/no); spoken or written English language
inadequate to take part in interviews or complete
questionnaires (yes/no); and another indication for taking
antidepressants, e.g. neuropathic pain (yes/no).
Data collection at baseline assessment is face to face
but data are entered online using i-survey (University of
Southampton secure online survey system) where pos-
sible. Data collection at 3 and 9months are through ei-
ther online i-survey or postal follow-up, with one
reminder after 2 weeks, and subsequent face-to-face or
telephone follow-up to obtain the outcomes for patients
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who do not complete the i-survey or return their ques-
tionnaires by post. Postal questionnaires are accompan-
ied by an explanatory letter requesting return of
completed questionnaires within 2 weeks if possible.
Data collection at 6 and 12months is face to face. Partic-
ipants are given a £10 gift voucher for their time at the
first (face-to-face) assessment and again at the final 12 -
month (face-to-face) follow-up. Relevant information on
consultations at the practice and use of services outside
the practice is also extracted from patients’ medical re-
cords by practice staff at the end of the study, assuming
the patients have given consent for this.
Data collection summary
The data collection summary is shown in Table 1.
Plans to promote participant retention and complete
follow-up {18b}
We ask participants when we screen them if they are
happy to receive texts. If participants are happy to
disclose their mobile number, we keep in regular contact
with them using the University of Southampton text
messaging service. Text messages are sent to remind
participants about appointments and completing online
questionnaires.
If patients are uncontactable when trying to arrange
their face-to-face follow-ups at 6 and 12months, postal
questionnaires are sent together with a shopping vou-
cher, and a compliment slip offering a telephone call to
complete the main outcome questionnaires (PHQ-9 and
EQ-5D-5L) if that is preferable to the patient. Patients’
practices are also contacted with a request to practice
staff to help the research team contact patients who are
uncontactable. If the patient has not been contactable
within 6 weeks of a follow-up point, they are deemed to
have been lost to follow-up at that point, but the same
rigorous approaches are made again at the next follow-
up point.
Data management {19}
Participant data are entered on laptop computers on site
and then transferred to electronic databases and stored
at the University of Southampton. Data stored are
checked for missing or unusual values (range checks)
and checked for consistency within participants over
time. Any suspect data are returned to the researcher or
practice in the form of data queries.
Confidentiality {27}
Participant data are pseudo-anonymised by assigning
each participant an identifier code used to identify the
participant during the study and for any participant-
specific clarification between the University of South-
ampton as sponsor and participating general practices.
The informed consent form specifies the participant
data to be collected and how it is managed or might be
shared, including handling of all patient identifiable data
and sensitive patient identifiable data adhering to
relevant data protection law. Only trained personnel
assigned specific roles are granted access to the
electronic patient data.
Data will be retained at the University of Southampton
in accordance with the General Data Protection
Regulation (2018) act. The participants’ medical records
and other relevant data may also be reviewed by
appropriate qualified personnel independent from the
trial team who are appointed to audit the study,
including representatives of the competent authority.
Details will remain confidential and participants’ names
will not be recorded outside the university.
Plans for collection, laboratory evaluation and storage of
biological specimens for genetic or molecular analysis in
this trial or for future use {33}
This trial does not involve collecting biological
specimens for storage.
Statistical methods
Statistical methods for primary and secondary outcomes
{20a}
A full and detailed statistical analysis plan will be
developed prior to the final analysis of the trial. The
main features of the statistical analysis plan are as
follows.
Intention-to-treat (ITT) analyses at the patient level
will be performed using mixed logistic/linear regression
models, controlling for baseline values, stratification
variables and potential confounders as appropriate.
Practices will be modelled as a random effect to allow
for the clustering of patients within practices. Patterns of
missing data will be explored, sensitivity analysis will be
used to explore the impact of missingness, and
imputation of missing data will be used. In a non-
inferiority trial where some patients do not comply with
treatment as randomised, the difference between the
arms can appear reduced and the groups look more
similar, leading to the incorrect conclusion of non-
inferiority. A per-protocol analysis would analyse indi-
viduals based on their compliance with treatment as ran-
domised, excluding non-compliant participants, giving a
more conservative estimate of effect for non-inferiority
[38]. However, the exclusion of some participants after
randomisation can potentially lead to bias. Therefore, we
will present both intention-to-treat and per-protocol
analyses.
We will also undertake a complier-average causal ef-
fect analysis, which is another approach for dealing with
non-compliance that compares compliant participants in
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the intervention group with those in the control group
whose characteristics are similar enough to the interven-
tion group compliers to suggest they too would have
complied with the intervention given the opportunity to
do so [39]. Compliance for these analyses in the inter-
vention arm will be defined as completing the first ses-
sion of the LifeGuide programme within 6 months of
recruitment (anticipating >90%). The first session will
have information about antidepressant treatment, the ra-
tionale for attempting withdrawal, and how withdrawal
should be attempted under supervision. We would ex-
pect patients to benefit from that session even if they do
not log on again. Compliance in the control arm will be
defined as having consulted the GP/NP to have their
antidepressant treatment reviewed within the 6-month
follow-up period.
For the primary outcome, we will report the analyses
based on all three approaches and interpret the findings
cautiously in light of any differences between approaches
that may emerge. This analysis will form the core of the
publication of the trial results.
For secondary outcomes, the analyses will use a similar
modelling approach to that set out for the primary outcome,
with mixed logistic/linear regression models as appropriate,
with a random effect for practice, controlling for baseline
values, stratification variables and potential confounders as
appropriate. Discontinuation of antidepressants will be
evaluated at the 6-month time point. All other secondary
measures will be analysed using a repeated measures ap-
proach with measures clustered within patients over time in
addition to the clustering of patients within practice. The
models will control for stratification variables and potential
confounders as appropriate and, where a baseline measure
for the outcome is available, will control for the baseline
value as well.
Health economics analysis
For the full trial, our proposed economic evaluation will
be taken from an NHS and personal social services
perspective with a sensitivity analysis from a societal
perspective. The outcome will be expressed as
incremental cost per point improvement in the PHQ-9
clinical outcome, incremental cost per discontinuation
of antidepressants, and incremental cost per quality-
adjusted life year (QALY) gained (cost utility analysis).
Case note review at 12 months will augment the 6-
monthly patient reports of health and social service re-
source use. All items will be costed using appropriate
data (e.g. Personal Social Service Research Unit, NHS
reference costs), with informal care costed at minimum
wage level. The primary analysis will be at 12 months.
Personal costs will include patient and carer time off
work, personal expenses, use of the internet, and travel.
Itemised resource usage will be weighted by associated
unit costs and aggregated over 12 months. QALYs will
be estimated by the area under the curve approach.
A generalised linear mix model will be used to
estimate the differences in costs and QALYs (using both
EQ-5D-5L and six-item Short Form utilities), adjusting
for baseline characteristics including socio-economic
deprivation and internet use. Where appropriate, we will
estimate incremental cost-effectiveness ratios. We will
estimate mean values and 95% percentiles using non-
parametric bootstrapping, and use these to estimate
cost-effectiveness acceptability curves. Major assump-
tions in the costing and quality of life analysis will be
tested through sensitivity analyses. A decision analytic
model will be developed to extrapolate the cost effective-
ness beyond the trial period covering the potential risk
of recurrence if the intervention proves to be effective in
terms of improvements in QALYs up to 12months. The
health economics analysis will be published.
Interim analyses {21b}
No a priori interim analyses are planned. Full details of
the analyses to be undertaken will be set out in a
statistical analysis plan, to be approved by the
independent PSC. The IDMC will review outcome and
safety data regularly during the trial, advising the PSC
on continuation of the trial.
Methods for additional analyses (e.g. subgroup analyses) {20b}
No a priori subgroup analyses are planned. Any post-
hoc analyses will be exploratory only.
A qualitative process evaluation will also be carried out.
Process evaluation is an important tool for understanding
both the dynamics and the outcomes of clinical trials, and
the normalisation process theory (NPT) [40] is a
conceptual toolkit developed for this purpose. NPT
focuses on understanding the mechanisms that promote,
and the factors that inhibit, sense-making, participation,
action and monitoring by participants in implementation
processes.
The objectives of the process evaluation in the trial are
to identify, characterise, and explain the perspectives of
patient and practitioner participants on the conduct of the
trial, and to construct a taxonomy of factors affecting both
the conduct of the trial and the potential for
normalisation of the use of the interventions in everyday
practice, outside of the trial situation. The analysis will
enable the construction of an implementation framework
of barriers and facilitators (patient and health system
factors) that need to be taken into account in the use of
the interventions in primary care practice.
The qualitative interviews will be transcribed and
emerging themes identified through inductive analysis
using the constant comparative method. We will draw
on insights from the wide range of studies that have
Kendrick et al. Trials          (2020) 21:419 Page 11 of 15
employed NPT, giving a basic structure to the topic
guide to be written in advance of the interviews.
However, we will also work prospectively and
inductively to ensure that we identify, characterise and
understand 1) disconfirming evidence and deviant cases,
and 2) processes that are not accounted for within NPT.
Methods in analysis to handle protocol non-adherence and
any statistical methods to handle missing data {20c}
We will examine the structure and pattern of missing
data and, if appropriate, will present a sensitivity analysis
based on data imputed using a multiple imputation
model. As described above, data will be analysed on an
intention-to-treat basis, on a per-protocol basis, and
using a complier-average causal effect analysis.
Plans to give access to the full protocol, participant-level
data and statistical code {31c}
The anonymised quantitative datasets (but not the
qualitative interview data) generated during the current
study may be available upon request from TK (ark1
@soton.ac.uk) from 31 August 2023, depending on the
types of analyses planned and submission of a peer-
reviewed, funded, and ethically approved proposal. The
trial dissemination group, whose purpose is to oversee the
planned outputs from the trial and agree on whether data
are shared, comprises the Chief Investigator (TK) in
Southampton and one co-applicant from each of the other
two centres: Liverpool (CD) and Hull (UM).
Oversight and monitoring
Composition of the coordinating centre and trial steering
committee {5d}
TK, CD and UM lead regular local study team meetings
at Southampton, Liverpool and Hull, respectively, and
overall REDUCE Management Team Meetings take
place every month through teleconferencing to review
progress and give advice on the conduct and
management of the study. The Management Team
Meeting includes representatives with expertise in
general practice, psychiatry, psychology, sociology,
statistics and health economics, and is supported by
three PPI contributors and Clinical Trials Unit staff
involved in the day-to-day running of the trial.
An independent PSC has been set up to oversee trial
conduct, consisting of an academic GP (chair), academic
psychologist, statistician and two patient representatives.
Composition of the data monitoring committee, its role and
reporting structure {21a}
The IDMC consists of an academic psychiatrist (chair),
academic GP and a statistician. The IDMC will review
outcome and safety data regularly during the trial,
advising the PSC on continuation of the trial.
Adverse event reporting and harms {22}
Any adverse events reported by patients or practitioners
will be brought to the attention of the Trial Coordinator
and Chief Investigator (CI) or, in the absence of the CI,
one of the Principal Investigators (PIs). The CI or PI will
decide whether or not to inform sponsor or the Research
Ethics Committee (REC), PSC or IDMC. The report will
include the event, when the information was reported,
assessment of seriousness and likely relationship to
participation in the trial.
All serious adverse events will be reported to the CI
and the Trial Coordinator within 24 h of the local site
becoming aware of the event. We will record the nature
of the event, date of onset, severity, corrective therapies
given, outcome, causality (i.e. unrelated, unlikely,
possible, probably, definitely) and expectedness. The CI
will assign the causality and expectedness of the event
and the term should be in accordance with the latest
version of MedDRA and grades given in accordance
with the NCI CTCAE v4.03. Additional information will
be provided as soon as possible if the event has not
resolved at the time of reporting.
The CI or Programme Manager will notify the REC of
related and unexpected serious adverse events occurring
during the study according to the following timelines:
fatal and life-threatening within 7 days of notification
and non-life threatening within 15 days. Adverse events
will also be reported to the IDMC who will advise the
PSC about continuation and whether interim analyses
are needed. The PSC will work with the IDMC and be
kept informed by the CI, PI, or Trial Coordinator. If an
extension was requested it would be the responsibility of
the PSC to look in detail as to why this was needed and
give an opinion which would inform the funder (NIHR)
and the sponsor (University of Southampton).
Frequency and plans for auditing trial conduct {23}
The trial teams at Southampton, Liverpool and Hull
undertake a number of internal audits of their own systems
and processes regularly. In addition, participants’ trial
records, medical records and other relevant data may be
reviewed by appropriate qualified personnel independent
from the trial teams appointed to audit the study, including
representatives of the sponsor and of the Health Research
Authority. Details will remain confidential and participants’
names will not be recorded outside the universities.
Plans for communicating important protocol amendments
to relevant parties (e.g. trial participants, ethical
committees) {25}
Proposed important protocol modifications (e.g. changes
to eligibility criteria, outcomes and analyses) will be
discussed with the co-investigators before seeking ap-
proval from the Health Research Authority and REC,
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and subsequently communicated to the trial registry and
journals in any publications arising.
Dissemination plans {31a}
The results of the REDUCE trial will be disseminated to
participating practices in summary form, as well as
academic audiences via publication in peer-reviewed
journals and general practice trade publications. We will
also publicise our findings through existing primary care
networks and patient groups. Summary trial results will
be available on the websites of the participating univer-
sities. The trial dissemination group, whose purpose is
to oversee the planned outputs from the trial and agree
on whether data are shared, comprises the CI TK in
Southampton and one co-applicant from each of the
other two centres: Liverpool (CD) and Hull (UM).
Discussion
Helping patients reduce and stop antidepressants is often
challenging for practitioners and time consuming for very
busy primary care practices. If providing internet and
telephone support enables more patients to stop treatment
without increasing depression we will spread the
intervention throughout the NHS, publishing practical
guidance for professionals and advice for patients to follow,
publicised through patient support groups.
Trial status
This paper is based on version 1.4 of the protocol, dated
28 November 2019, when the REDUCE trial is still
recruiting. The protocol was initially approved by the
North of Scotland Research Ethics Committee (REC 1)
on 2 September 2019 (reference no. 19/NS/0144). A
substantial amendment was approved by the REC and
Health Research Authority on 16 December 2019.
Recruitment of practices began on 1 December 2019,
and the approximate date when recruitment of patients
will be completed is 30 June 2021. The end of the study
is defined as the date of the last follow-up visit of the
last patient (expected to occur 12 months after the last
patient is recruited).
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